

SUPPLEMENTARY INFORMATION

Katacine is a new ligand of CLEC-2 that acts as a platelet agonist

Luis A. Morán^{1,2}, Ying Di², Marcin A. Sowa^{1,3}, Lidia Hermida-Nogueira¹, María N Barrachina^{1†}, Eleya Martin², Joanne C. Clark², Todd H. Mize⁴, Johannes A. Eble⁵, David Moreira¹, Alice Y. Pollitt³, María I. Loza¹, Eduardo Domínguez¹, Steve P. Watson², Ángel García¹

¹Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidad de Santiago de Compostela, and Instituto de Investigación Sanitaria (IDIS), Santiago de Compostela, Spain

²Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, UK

³Institute for Cardiovascular and Metabolic Research (ICMR), School of Biological Sciences, University of Reading, Reading, UK

⁴Advanced Mass Spectrometry Facility, Biosciences, College of Life and Environmental Sciences, University of Birmingham, UK

⁵Institute for Physiological Chemistry & Pathobiochemistry, University of Münster, Germany

†Current affiliation: Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, USA


Supplementary Methods

Mouse platelet isolation


Blood was taken from anaesthetised wild type (WT) C57BL/6 mice into 10% ACD washed platelets, PRP was obtained by centrifugation at 200 x g for 20 minutes, followed by addition of 0.2 µg/ml prostacyclin and centrifugation at 1000 x g for 10 min. Platelets were resuspended in Tyrode's buffer (134 mM NaCl, 0.34 mM Na₂HPO₄, 2.9 mM KCl, 12 mM NaHCO₃, 20 mM HEPES, 5mM glucose, 1 mM MgCl₂, pH 7.3), followed by an additional centrifugation step as above. Platelets were resuspended and allowed to rest for 30 min at room temperature.

Supplementary Table 1. Detailed information of top compounds identified during ALPHA screening as a disruptor of CLEC-2 and podoplanin interaction and ranked according to their potency showed on the concentration-response curves on Figure 1.


Label	Name	MW	IC50 (μ M)	SMILE CODE
A	Sennoside A	862.74	1.3	<chem>OC[C@H]([C@H]([C@@H]([C@H]1O)O)O)[C@@H]1Oc1cccc([C@H]([C@H](c2cccc(O[C@H]([C@@H]([C@H]3O)O)O[C@H](CO)[C@H]3O)c22)c3cc(C(O)=O)cc(O)c3C2=O)c2c3c(O)cc(C(O)=O)c2)c1C3=O</chem>
B	Katacine	914.77	2.7	<chem>O[C@H]1[C@@H](c(cc2O)cc(O)c2O)Oc2c([C@H]([C@H]3O)c(c(O)cc(O)c4[C@H]([C@H]5O)c(c(O)cc(O)c6)c6O[C@@H]5c(cc5O)cc(O)c5O)c4O[C@H]3c(cc3O)cc(O)c3O)c(O)cc(O)c2C1</chem>
C	4-{{4-(pyridin-2-yl)-1,3-thiazol-2-yl}amino}phenol	269.32	2.9	<chem>Oc(cc1)ccc1Nc1nc(-c2ncccc2)cs1</chem>
D	6-dipyridin-2-ylpyrimidin-4-amine	357.41	5.3	<chem>C(CNc1cc(-c2ncccc2)nc(-c2ncccc2)n1)Cn1cnc1</chem>
E	N-allyl-6-phenyl-2-pyridin-2-ylpyrimidin-4-amine	288.35	6.3	<chem>C=CCNc1cc(-c2cccc2)nc(-c2ncccc2)n1</chem>
F	N'-[(E)-(3-ethoxy-2-hydroxyphenyl)methylidene]pyridine-2-carbohydrazide	285.30	6.7	<chem>CCOc1cccc(/C=N/NC(c2ncccc2)=O)c1O</chem>



Supplementary Figure 1. Katacine does not induce an increase in tyrosine phosphorylation levels of the FcR γ -chain in human platelets. Representative immunoblots of platelet lysates (4×10^8) stimulated with DMSO 0.1% (negative control), 100 nM rhodocytin, 10 μ M katacine, or 3 μ g/mL CRP (positive control). Lysates were run by SDS-PAGE and transferred to a PDVF membrane and incubated against the anti-tyrosine antibody (4G10) (A). The same membrane was incubated against the anti-FcR antibody (B).



Supplementary Figure 2. Molecular docking suggested an additional highly scored binding site on CLEC-2 for katecine interaction on the opposite site to the canonical binding site reported for other ligands (enclosed in red circle). Autodock vina has predicted a binding energy of -6.9 kcal/mol for katecine binding on Ser-166 and Asn-194. This finding may indicate a potential allosteric binding site for CLEC-2, previously unreported.



Supplementary Figure 3. Katacine does not induce platelet aggregation or protein tyrosine phosphorylation in mouse platelets. Ai) Representative traces of mouse washed platelets (2×10^8 platelets/mL) stimulated with $10 \mu\text{M}$ katacine or 100nM rhodocytin. Aii) Column chart representing the mean aggregation \pm SD of three independent experiments. B) Representative immunoblots of mouse platelet lysates (4×10^8 platelets/mL) stimulated with 0.1% DMSO (negative control), 100 nM rhodocytin (positive control) or $10 \mu\text{M}$ katacine.